Around 40–50% of all triple-negative breast cancer (TNBC) patients achieve a pathological
complete response (pCR) after treatment with neoadjuvant chemotherapy (NAC). The …

Breast cancer is a disease encompassing a spectrum of molecular subtypes and clinical
presentations, each with distinct prognostic implications and treatment responses. Breast …

The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has
revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust …

The role of neoadjuvant therapy (NAT) for localized breast cancer has evolved tremendously
over the past several years. Currently, NAT is the preferred option for high-risk early triple …

For decades, chemotherapy has been the mainstay of breast cancer treatment. Novel
therapies are expanding the therapeutic options and altering the treatment algorithms to …

Simple Summary Triple-negative breast cancer (TNBC) is the most aggressive breast cancer
subtype accounting for approximately 10–20% of all cases. Due to a lack of actionable …

Neoadjuvant chemoimmunotherapy (NACIT) has been shown to improve pathologic
complete response (pCR) rates and survival outcomes in stage II-III triple-negative breast …

Opinion statement Recently, the addition of PD-1 pathway targeting immune checkpoint
inhibitors (ICI) to standard neoadjuvant chemotherapy for early-stage triple-negative breast …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and now represent
the mainstay of treatment for many tumor types, including triple-negative breast cancer and …

We present an integrated single-cell RNA sequencing atlas of the primary breast tumor
microenvironment (TME) containing 236,363 cells from 119 biopsy samples across eight …